Compound News and Research

RSS

Researchers discover non-opioid therapeutic for relieving neuropathic pain

Among the most difficult types of pain to alleviate is neuropathic pain, pain that is usually caused by damage to nerves in various body tissues, including skin, muscle and joints.

31 Jan 2024

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

From Enterprise Therapeutics Ltd 31 Jan 2024

Improving mitochondrial metabolism could be a potential therapeutic target for Alzheimer's

Nerve cells in the brain demand an enormous amount of energy to survive and maintain their connections for communicating with other nerve cells.

30 Jan 2024

Puffed-up MOFs show improved performance as drug-delivery vehicles

The spongelike structure of metal organic frameworks (MOFs) allows these polymers to possibly carry and deliver a range of therapeutic compounds.

27 Jan 2024

New study opens unprecedented opportunities for bioengineering vaccine adjuvants

A valuable molecule sourced from the soapbark tree and used as a key ingredient in vaccines, has been replicated in an alternative plant host for the first time, opening unprecedented opportunities for the vaccine industry.

26 Jan 2024

Scientific review explores adzuki beans' efficacy in diabetes prevention and management

Adzuki bean (Vigna angularis) supplementation to prevent and manage type 2 diabetes (T2D).

25 Jan 2024

Curcumin spray shows promise in fighting SARS-CoV-2 and flu viruses

A study in the Virology Journal reveals a curcumin-containing oro-nasal film spray with potential antiviral activity against SARS-CoV-2 and influenza viruses, boosting mucosal immunity without cytotoxic effects.

24 Jan 2024

Prepared for the next virus pandemic: The APPEAL project

In collaboration with 12 partners from 6 countries, MatTek is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics.

From MatTek Corporation 24 Jan 2024

Cancer drug holds promise for shrinking polycystic kidney cysts

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function.

22 Jan 2024

UMass Amherst researcher aims to tackle bone damage in metastatic cancer

For some patients whose cancer has spread to their bones, the ensuing treatment can be more physically damaging than the original disease, leading to increased bone loss and fracture.

22 Jan 2024

COST Action bridges the gap in cancer immunotherapy research

Cancer is still a leading cause of death worldwide. Globally, there were an estimated 20 million new cases of cancer and 10 million deaths.

20 Jan 2024

AI scores breakthrough in anemia treatment with novel PHD inhibitor

Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal focusing on critical studies about molecular structure and biological activity, has published the company's discovery of a novel PHD inhibitor for the treatment of anemia.

19 Jan 2024

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.

19 Jan 2024

New structural insights pave the way for drug-resistant malaria therapies

Structural insights into a potent antimalarial drug candidate's interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.

18 Jan 2024

Uncovering the cellular roots of spinocerebellar ataxia type 6

Researchers from McGill University, led by Professor Alanna Watt of the Department of Biology, have identified previously unknown changes in brain cells affected by a neurological disease.

18 Jan 2024

New targeted therapy eliminates cancer with zero side effects

Johannes Karges develops anti-cancer agents that work in a targeted manner, rather than adversely affecting the entire body.

18 Jan 2024

Vanderbilt launches $13 million trial to test repurposed drugs for Rett syndrome

Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome.

16 Jan 2024

3D nanomatrix vascular sheet model for high-throughput atherosclerosis drug testing

A groundbreaking 3D, three-layer nanomatrix vascular sheet that possesses multiple features of atherosclerosis has been applied for developing a high-throughput functional assay of drug candidates to treat this disease, University of Alabama at Birmingham researchers report in the journal Biomaterials.

12 Jan 2024

When mass spectrometry redefines the pharma industry

In this new episode of omg OMx, Kate Stumpo speaks to Bruker's Mike Greig about the incredible potential of mass spectrometry in pharma.

From Bruker Life Sciences Mass Spectrometry 12 Jan 2024

UTEP researchers unveil promising new weapon against leukemia and lymphoma

Researchers at The University of Texas at El Paso have identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of therapy.

11 Jan 2024